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Introduction
Lung cancer is one of the most common cancers in humans, as well as the leading cause of cancer-related death worldwide (Jemal et al. 2011) . Although diagnosis at an early stage is increasing with the introduction of low-dose computerized tomography screening, lung cancer is still a devastating disease which has a very poor prognosis (Aberle et al. 2011 ).
Lung cancer can be classified based on histopathologic findings: adenocarcinoma is the most common type (Travis et al. 2005) . Recently, deeper understanding of the major genetic alterations and signaling pathways involved has suggested a reclassification of lung adenocarcinoma based on underlying driver mutations. Cancer cells with these genetic alterations have survival and growth advantages over cells without such changes (Haber et al. 2007 ). Currently, approximately ten driver genes have been discovered in lung adenocarcinoma (Pao et al. 2011) . Clinical trials using new chemotherapeutic agents targeting such alterations have demonstrated remarkable improvements in patient outcome, for example gefitinib (Maemondo et al. 2010; Mok et al. 2009 ) and crizotinib (Kwak et al. 2010 ) for lung adenocarcinoma harboring EGFR mutations and EML4-ALK (Soda et al. 2007 ) fusion, respectively. More recently, not only point mutations but also tyrosine kinase gene fusions, such as KIF5B-RET, were also identified as driver mutations (Ju et al. 2012 ).
Nevertheless, we still do not know the molecular drivers of about 40% of lung adenocarcinomas (Pao et al. 2011) . Interestingly, the frequencies of some driver mutations have been shown to be significantly different between ethnic groups (Shigematsu et al. 2006) , and therefore comprehensive cancer genome studies in a range of human populations will help to find new molecular alterations which can be targeted in treatments of lung cancer.
In this study, we broadly surveyed genetic alterations in 200 fresh surgical specimens of lung adenocarcinoma in Koreans. 87 of these were analyzed by transcriptome sequencing Table 7) . Among 43 fusion genes where PCR primer was available, 39 were successfully validated (Supplementary Table 7 ). Interestingly, the four invalidated fusion genes all included a surfactant gene (i.e. SFTPB or SFTPA2) or H19, wildtype gene expression of which were extremely high (> ~2,000 RPKM) in the corresponding specimens. This indicates that the fusion transcript may have been artificially synthesized during sequencing library construction.
Of the fusion genes we identified, 8 were chimeric tyrosine kinases which are highly likely to play an important role in cancer development. Cancer specimens carrying one of the tyrosine kinase fusions (n=10) did not harbor any of the canonical point driver mutations (pvalue = 2.12 x 10 -4 ; Supplementary Table 8 ). Of these eight fusion genes, four have been reported previously (EML4-ALK (Soda et al. 2007 ), KIF5B-RET (Ju et al. 2012; Kohno et al. 2012; Lipson et al. 2012; Takeuchi et al. 2012) , CD74-ROS1 (Rikova et al. 2007; Takeuchi et al. 2012 ) and SLC34A2-ROS1 (Rikova et al. 2007; Takeuchi et al. 2012) ), and we refer to them here as "canonical transforming fusion genes". The remaining four fusion genes were novel (CCDC6-ROS1, FGFR2-CIT, AXL-MBIP and SCAF11-PDGFRA) ( Figure 3A ). Of these four novel fusion genes, CCDC6-ROS1, FGFR2-CIT and AXL-MBIP carry protein tyrosine kinase domains and dimerization units (Alberti et al. 2003; Ju et al. 2012 ) (coiled-coil or leucine zipper domains), both of which are essential to activate chimeric tyrosine kinases.
The SCAF11-PDGFRA fusion is an example of promoter swapping (Kas et al. 1997) .
Because the cancer specimens harboring these four novel fusion genes did not carry any known driver mutations (neither canonical point driver mutations (n=47) nor canonical transforming fusion genes (n=6); p-value = 0.021; Supplementary Table 8), they may play 1 0 never-smokers. There was a significant difference in the number of point mutations between the two groups ( Figure 4A ). On average, smokers had significantly more amino-acid-altering single nucleotide and short-indel mutations (65.0 and 20.6 mutations per cancer tissue of smokers (n=40) and never-smokers (n=33), respectively; p-value = 0.0011). Interestingly, the amount of smoking (pack-years) was positively correlated with the number of somatic point mutations in the cancer genome (p-value = 0.01; Supplementary Figure 6 ). We also identified differences in mutational spectrums. Cancer tissues from smokers showed similar mutational signatures to those identified previously (Pleasance et al. 2010 ) (C>A transversion most frequent; T>G transversion least frequent), whereas cancers from neversmokers did not. C>A transversion was more frequent in smokers (p-value = 3.1 x 10 -6 ),
while T>G transversion was more common in never-smokers (p-value = 8.1 x 10 -14 ) ( Figure   4B ). In addition, from the gene expression profiles (Supplementary Information; Supplementary Table 10 ; Data access), we detected a total of 6,719 cancer outlier genes (COGs), which were extremely highly expressed in a small number of cancer tissues (Supplementary Table 11 ). The number of COGs per cancer tissue varied markedly ( Figure   4C ), ranging from 0 to 989. The lung adenocarcinomas of smokers carried significantly more COGs than those of never-smokers (p-value = 0.0078; Figure 4C and 4D; Supplementary Figure 7 ). These findings demonstrate that lung adenocarcinoma in smokers harbors more somatic mutations and greater perturbation of gene expression levels.
Co-localization of over-and under-expressed genes
Next, we assessed the gene expression pattern of each specific cancer specimen relative to the general transcriptional landscape of all 87 cancer tissues. After identifying genes which were relatively over-expressed and under-expressed in each cancer, we interestingly observed that these sets were spatially grouped together in the genome ( Figure 5A ;
Supplementary Figure 8 ). We defined those regions containing such groups as jointly 1 1 regulated blocks (JRBs). The number of JRBs was highly variable among cancer tissues. In order to investigate the cause of these JRBs, we performed comparative genomic hybridization (CGH) array (Park et al. 2010 ) experiments on a subset of cancer samples (n=9). Interestingly, combined analyses between array results and JRBs showed that ~ 70%
of JRBs can be explained by the copy number status of the cancer genome ( Figure 5A and 5B). Recent reports have also shown that cancer genomes harbor large hypo-methylated (and hyper-methylated) blocks (Hansen et al. 2011; Wen et al. 2009 ), suggesting the combined effect of somatic copy number alterations and DNA methylation patterns are likely to induce the diversity of gene expression profiles in cancer tissues.
We merged the JRBs identified from 87 lung adenocarcinoma samples. This clearly showed that the blocks are not randomly distributed in the genome ( Figure 5C ). For example, gene expression is frequently increased on the short arm of chromosome 7, while expression is frequently decreased on the short arm of chromosome 3. These patterns correlate with frequent copy number alterations of cancer genomes identified in previous studies (Job et al. 2010; Weir et al. 2007 ).
Lymph node metastasis and TP53 mutation
We investigated the correlation of somatic alterations with lymph node metastasis (information for lymph node metastasis is available in Supplementary Table 12 ).
Summary of driver mutations in lung adenocarcinoma
We summarize the mutational profiles of the 200 lung adenocarcinomas in Figure 6 , including the results from transcriptome sequencing and from screening tests (99 with EGFR mutations, 6 with KRAS mutations and 7 with EML4-ALK fusions). Table 13 ).
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Discussion
The landscape of lung cancer genomes has been widely investigated using genotyping microarray, sequencing of targeted cancer genes, CGH array, exome sequencing and wholegenome sequencing (Beroukhim et al. 2010; Ding et al. 2008; Lee et al. 2010) . These studies provided the large repertoire of known genomic abnormalities in cancer genes (i.e. including a large proportion of female patients, the predominance of adenocarcinoma over other types and a high frequency of EGFR point mutations compared to Europeans.
Investigation of such features may provide insights for the treatment or prevention of lung cancer in East Asians. Yet large-scale analysis of lung cancer genomes has not been performed in this ethnic group.
In this study, we have extensively analyzed the transcriptomes of 87 lung adenocarcinomas in Korean patients. Additional whole-exome and transcriptome sequencing for the adjacent paired-normal tissues was also performed to increase the specificity in identifying somatic mutations.
Transcriptome sequencing is a powerful tool to understand cancer because it captures a snapshot of diverse aspects of transformed cells. For instance, through whole-genome or whole-exome sequencing we can check for the presence of somatic mutations in cancer.
However, transcriptome sequencing also provides a picture of dynamic consequences rather than just the mutations themselves. We can profile gene expression levels, gene fusions,
and alternative splicing events simultaneously, all of which contribute to the proliferation of cancer cells. Moreover, RNA-seq is a very sensitive tool to identify point mutations. For example, six specimens which were negative for EGFR point mutations in the conventional screening test were discovered to harbor EGFR point mutations by transcriptome sequencing in this study. We believe that RNA sequencing is likely to outperform genome sequencing in detection of cancer driver mutations, especially when tumor purity is relatively low. Genes with driver mutations in cancer cells are likely to be more highly expressed than in normal cells, therefore enhancing the signal-to-noise ratio in RNA-seq. For both approaches, it is important that systems are implemented which ensure the efficient collection and preservation of cancer tissues from clinic to bench.
Tumor heterogeneity is an important issue in cancer genome studies (Marusyk et al. 2010; Shah et al. 2012) . Cancer tissue specimens with a low proportion of cancer cells require deeper read-depth when sequencing. We collected specimens from the center of tumors to attempt to obtain pure samples. The differences in numbers of somatic mutations per case as well as intrinsic variability in read allele frequency in RNA-seq (i.e. allele-specific expression and expression differences between cells) do not allow accurate estimation of tumor heterogeneity from cancer transcriptome sequencing data. Ignoring these issues, the distribution of read allele frequencies in cancer transcriptome sequencing for somatic point mutations suggests that the purity of the 87 specimens studied is approximately 80% on average (Supplementary Figure 9) . In addition, to increase the sensitivity in detection of All the cancer and adjacent paired-normal tissue specimens used in this study were acquired from surgical specimens. Cancer and normal tissue specimens were grossly dissected and preserved immediately in liquid nitrogen after surgery. For RNA-seq, we extracted RNA from tissue using RNAiso Plus (Takara Bio Inc.), followed by purification using RNeasy MinElute (Qiagen Inc.). RNA was assessed for quality and was quantified using an RNA 6000 Nano
LabChip on a 2100 Bioanalyzer (Agilent Inc.). The RNA-seq libraries were prepared as previously described (Ju et al. 2011 ).
For exome sequencing of matched normal tissues (and cancer specimens LC_C5 and LC_C21 for validation purposes), genomic DNA was extracted from normal lung. Genomic DNA (3μg) from each sample was sheared and used for the construction of a paired-end sequencing library as described in the protocol provided by Illumina. Enrichment of exonic sequences was then performed for each library using the SureSelect Human All Exon 50Mb
Kit (Agilent Inc.) following the manufacturer's instructions.
Libraries for RNA and exome sequencing were sequenced with Illumina TruSeq SBS Kit v3 on a HiSeq 2000 sequencer (Illumina Inc.) to obtain 100-bp paired-end reads. The image analysis and base calling were performed using the Illumina pipeline (v1.8) with default settings.
Screening tests
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Screening genetic tests were performed for identification of three well-known driver mutations in a subset of the 200 lung adenocarcinoma tissues as previously described: (1) 
Smoking history
Of the 87 individuals whose cancer specimens were RNA sequenced, smoking history before diagnosis of lung cancer was provided by 83 (47 smokers, 36 never-smokers and 4 unknowns). Information about the amount of smoking (pack-years) was available for 23 out of 47 smokers.
Sequence analyses
RNA and exome sequencing reads were aligned to the NCBI human reference genome assembly (build 37.1) using GSNAP (Wu et al. 2010 ) with allowance for 5% mismatches. In the same manner, the RNA sequencing reads were also aligned to a cDNA set consisting of 
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Somatic single nucleotide and short indel discovery
We first identified single nucleotide variations (SNVs) and short indel variants in cancer using the transcriptome sequencing data. To minimize false positive calls generated by misalignment, we used variant calls commonly identified from both the genome and the mRNA alignment. SNVs were defined according to the following three conditions: (i) the number of uniquely-mapped reads at the position should be ) were assumed to be unrelated to cancer transformation and were removed. These filtration steps might fail to remove some rare germline variants if the position was insufficiently covered in normal exome and transcriptome sequencing. However, we mostly focused on recurrent mutations in the later analysis, which are highly unlikely to be rare germline variants. Of note, among the 87 cancer specimens where RNA sequencing was performed, 11 did not have whole-exome sequencing of normal counterparts. Therefore, our lists of somatic mutations for the 11 cancer specimens are likely to include more rare germline variants than those of the other specimens. We did not consider the 11 specimens in the statistical analysis of the number of somatic mutations and smoking history of lung cancer patients.
Fusion gene detection
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We detected in-frame fusion genes by utilizing the GFP software described in our previous report (Ju et al. 2012) . Briefly, the method makes use of discordant read pairs, where two ends of a pair are mapped to different genes and exon-spanning reads across the exonic fusion breakpoint of chimeric transcripts. Additional filtration cascades (homology filter, fusion-spanning read filter and the fusion point filter) were applied to remove false positives (Ju et al. 2012) . In addition to GFP analysis, we also assessed read depth along each exon of tyrosine kinases (e.g. ALK, RET and ROS1), since abrupt over-expression after fusion gene breakpoints is a hallmark of fusion for these genes (Ju et al. 2012; Lipson et al. 2012) (Supplementary Figure 3) . We do not report intrachromosomal fusions between adjacent genes (<200 kb) because these are assumed to be due to read-through transcription and so do not originate in genomic rearrangement, e.g. translocation, inversion or large deletion (Ju et al. 2012 ). Finally, off-frame fusion genes were removed.
Alternative splicing
First, exon-skipping reads were extracted from the collection of sequencing reads for each cancer sample. The GSNAP alignment tool conveniently allows reads to be split into two segments and mapped to different exons when genomic positions of exons are provided to the program. We collected those spliced sequencing reads where non-adjacent exons of a gene were joined and defined them as exon-skipping sequencing reads. For candidate skipped exons supported by at least two exon-skipping reads, we obtained the expression levels for the candidate exon and its neighboring exons in terms of RPKM. Since the expression level for an exon is correlated with the expression level for the gene from which it derives, the expression of the exons was normalized by the expression level of the gene to which they belong. Next, the fold changes between the 5' neighboring and the 3' neighboring exons and the candidate exon were calculated and averaged. With an assumption of normal 2 1 distribution, a z-value for the fold change was obtained by considering all the fold changes calculated in the same manner in all the normal samples (n=77). If any of the normal averaged fold changes was less than 0.9, the candidate skipped exon was not further considered because dropped coverage was not specific to cancer.
Differentially Expressed Gene (DEG) selection
We selected DEGs by clustering genes by expression levels. First, genes with either RPKM < 1.0 or coefficient of variation (CV) < 0.7 were excluded to remove genes non-informative for clustering. This resulted in a total of 3,051 unique genes. Log 2 transformation and additional row-wise and column-wise normalization was applied: row-wise normalization was Finally, we referred to the hierarchical tree generated by the clustering process and selected three types of DEGs (cancer-UP, cancer-DOWN and mixed). 
Cancer outlier gene analysis
Jointly Regulated Block (JRB) identification
To generate the gene expression signatures of each cancer sample, we calculated the ratio of gene expression levels in a cancer tissue to the average expression levels in 77 adjacent normal tissues. The gene set for analysis was formed from 36,742 transcripts in the RefSeq database, which yielded 22,427 genes after filtering out redundant entries.
To quantify relative expression among cancer samples, we compared the gene expression ratio of a gene (gene A) in the i th cancer sample with the ratio in all 87 cancer tissues and calculated a normalized z-score as follows.
where SD is standard deviation of expression ratios.
During this process, genes with low expression levels (maximum expression < 3 RPKM) or genes with small variance in expressions (relative standard variation < 0.1) were removed, since signal to noise ratio for these genes is not sufficient. This left 16,419 genes for further investigation.
Given a set of z-scores, we calculated the moving-average of 10 z-scores by walking 2 3 through the chromosomes. An increased-expression JRB is defined as starting at a gene with a z-score > 1.5 and extending in both directions until a z-score < 0.5 is reached. Once its boundary is determined, the JRB must satisfy at least one of the three following criteria.
(i) more than 40 genes within a block (ii) more than 20 genes in a block, and an average zscore > 1.2 (iii) an average z-score > 2.0. On the other hand, we applied slightly different conditions in discovering decreased-expression JRBs to increase the sensitivity. A decreased-expression JRB is defined as starting at a gene with a z-score < -1.0 and extending in both directions until a z-score > -0.5 is reached. Then the JRB must satisfy at least one of the three following criteria. (i) more than 40 genes within a block (ii) more than 20 genes in a block with an average z-score < -0.8. (iii) an average z-score < -1.0.
The comparison of JRBs and copy number alterations provided by Comparative Genomic
Hybridization array was done by calculating the correlation (r 2 ) between the averaged zscores of JRBs and the averaged log2ratio values of probes within the same JRBs. CGH array analyses were performed using 9 cancer samples (LC_C7, LC_C21, LC_C25, LC_C35, LC_S19, LC_S23, LC_S39, LC_S42 and LC_S51) and their normal counterparts using a customized Agilent 180K CGH array platform (Park et al. 2010) . CGH array experiments were conducted according to the manufacturer's instructions (Agilent Inc.). Briefly, genomic DNA from cancer and adjacent-normal specimens were labeled by Cy-5 and Cy-3 dye, respectively, and hybridized. Log2 ratio was calculated by image analysis of CGH array using the CGH-105_Jan09 protocol (Agilent Inc.) for background subtraction and normalization.
Validation of fusion genes
Fusion genes were validated using PCR amplification of fusion gene breakpoints of chimeric cDNA and Sanger sequencing. The PCR reactions were 10 min at 95℃; 30 cycles of 30 sec 
Statistical analyses
The differences in number of somatic mutations and COGs between smokers and neversmokers ( Figure 4A and 4C) were tested using Student's t-test. Chi-square tests were applied on the difference in mutation spectrums ( Figure 4B ). Logistic regression analysis was performed to assess the relationship between somatic mutations (known or candidate driver mutations and TP53 mutations) and lymph node metastasis using gender, age, cancer stage and smoking status as covariates (Supplementary Table 12 ). Two-sided p-values were calculated for all these statistical tests.
Mutual exclusion and concurrence analysis
We carried out pair-wise mutual exclusion and concurrence analysis for genes that showed more than three mutations (including somatic point mutations, fusion genes and skipped exons). For a given pair of mutated genes A and B, we recorded the number of samples in possible four categories (A mutated only, B mutated only, A and B both mutated and neither).
Then Fisher's exact test was performed to infer the mutual dependency between the two genes. Once two genes were determined to be mutually dependent on each other by the test, their mutual exclusion/concurrence was determined by calculating Pearson's correlation coefficient, r (mutual exclusion: r < 0 and concurrence: r > 0).
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Data access
Gene Pie chart shows the distribution of driver mutations identified in 200 lung adenocarcinoma patients in this study. 
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